Enimmune Corp (安特羅生技) has obtained marketing approval from the Food and Drug Administration (FDA) for its EnVAX-A71 vaccine for enterovirus 71 (EV-71), becoming the nation’s first enterovirus vaccine completely made in Taiwan, it said yesterday.
After spending 13 years and NT$1.5 billion (US$49.77 million) on the research and development of the vaccine, Enimmune plans to start manufacturing and marketing it by the end of March, the company said in a statement, without disclosing customer order figures.
“It is possible that the vaccine would not be included in a national vaccination program initially, and consumers would need to pay for it themselves,” parent company Adimmune Corp (國光生技) told the Taipei Times yesterday.
Photo courtesy of Adimmune Corp
“However, we are working with the government, and hope that this vaccine could be included in a national vaccination program for children, as EV-71 is a common pathogen that causes polio-like syndrome and can lead to severe sickness,” Adimmune said.
As the vaccine would be administered to children younger than five and each child would need to have two shots, the total demand for the vaccine in Taiwan is estimated at 300,000 doses per year, the company said.
EnVAX-A71 is designed to act against genotype B4 of EV-71, which is widespread in Taiwan.
Enimmune has signed a memorandum of understanding with a Vietnamese state-run vaccine company to collaborate on EnVAX-A71 and is to complete a phase-three human test of the vaccine in the country in the near term.
In the long term, the company aims to enter the Southeast Asian market where demand for an enterovirus vaccine could exceed 20 million doses, it said, adding that it also plans to enter the Chinese market.
Enimmune’s revenue grew 72 percent year-on-year to NT$188 million last year, while Adimmune’s revenue grew 37 percent to NT$2.25 billion, companies data showed.
Local rival Medigen Vaccine Biologics Corp (高端疫苗) is also developing an enterovirus vaccine in Taiwan, but has not yet obtained marketing approval after submitting an application in 2021.
Shares of contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) came under pressure yesterday after a report that Apple Inc is looking to shift some orders from the Taiwanese company to Intel Corp. TSMC shares fell NT$55, or 2.4 percent, to close at NT$2,235 on the local main board, Taiwan Stock Exchange data showed. Despite the losses, TSMC is expected to continue to benefit from sound fundamentals, as it maintains a lead over its peers in high-end process development, analysts said. “The selling was a knee-jerk reaction to an Intel-Apple report over the weekend,” Mega International Investment Services Corp (兆豐國際投顧) analyst Alex Huang
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is expected to remain Apple Inc’s primary chip manufacturing partner despite reports that Apple could shift some orders to Intel Corp, industry experts said yesterday. The comments came after The Wall Street Journal reported on Friday that Apple and Intel had reached a preliminary agreement following more than a year of negotiations for Intel to manufacture some chips for Apple devices. Taiwan Institute of Economic Research (台灣經濟研究院) economist Arisa Liu (劉佩真) said TSMC’s advanced packaging technologies, including integrated fan-out and chip-on-wafer-on-substrate, remain critical to the performance of Apple’s A-series and M-series chips. She said Intel and Samsung
TRANSITION: With the closure, the company would reorganize its Taiwanese unit to a sales and service-focused model, Bridgestone said Bridgestone Corp yesterday announced it would cease manufacturing operations at its tire plant in Hsinchu County’s Hukou Township (湖口), affecting more than 500 workers. Bridgestone Taiwan Co (台灣普利司通) said in a statement that the decision was based on the Tokyo-based tire maker’s adjustments to its global operational strategy and long-term market development considerations. The Taiwanese unit would be reorganized as part of the closure, effective yesterday, and all related production activities would be concluded, the statement said. Under the plan, Bridgestone would continue to deepen its presence in the Taiwanese market, while transitioning to a sales and service-focused business model, it added. The Hsinchu
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has approved a capital budget of US$31.28 billion for production expansion to meet long-term development needs during the artificial intelligence (AI) boom. The company’s board meeting yesterday approved the capital appropriation plan for purposes such as the installation of advanced technology capacity and fab construction, the world’s largest contract chipmaker said in a statement. At an earnings conference last month, TSMC forecast that its capital expenditure for this year would be at the higher end of the US$52 billion to US$56 billion range it forecast in January in response to robust demand for 5G, AI and
RSS